Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

News Features

Should We Be Looking for ‘Occlusion MI’ Rather Than STEMI?

Todd Neale

May 19, 2025

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

News Features

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Michael O'Riordan

January 17, 2022

News Features

FFR’s Future: Negative Trials Spur Debate Over Technology’s Role

Michael O'Riordan

December 23, 2021

News Features

US Chest Pain Guidelines Will Change Practice, Though Gaps Remain

Yael L. Maxwell

December 06, 2021

News Features

Roughly 80% of ESC Guideline Writers Have Financial COIs

Michael O'Riordan

April 01, 2021

News Features

Top News in Coronary Artery Disease: 2018

Yael L. Maxwell

December 28, 2018

News Features

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

Shelley Wood

October 22, 2018

News Features

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Michael O'Riordan

November 27, 2017

News Features

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

Todd Neale

September 15, 2017

News Features

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

Michael O'Riordan

September 13, 2017

News Features

Be It Resolved: Lifestyle Changes for Patients Needing Cardiac Rehab May Be a Life or Death Matter

Michael O'Riordan

January 10, 2017

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Shelley Wood

December 30, 2016

News Features

The Bioresorbable Stent Story So Far: What Promise? What Price?

Michael O'Riordan

August 17, 2016

News Features

Opportunities Exist for Hospitals, Interventionalists to Stave Off Unnecessary Readmissions

July 28, 2015

News Features

CMS Penalties Spur Efforts to Reduce 30-Day Hospital Readmissions

July 21, 2015

Advertisement

Should We Be Looking for ‘Occlusion MI’ Rather Than STEMI?

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

FFR’s Future: Negative Trials Spur Debate Over Technology’s Role

US Chest Pain Guidelines Will Change Practice, Though Gaps Remain

Roughly 80% of ESC Guideline Writers Have Financial COIs

Top News in Coronary Artery Disease: 2018

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

Be It Resolved: Lifestyle Changes for Patients Needing Cardiac Rehab May Be a Life or Death Matter

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

The Bioresorbable Stent Story So Far: What Promise? What Price?

Opportunities Exist for Hospitals, Interventionalists to Stave Off Unnecessary Readmissions

CMS Penalties Spur Efforts to Reduce 30-Day Hospital Readmissions

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content